Gulf Pharmaceutical Industries P.S.C (JULPHAR) Stock Overview
Manufactures and sells medicines, drugs, and various other types of pharmaceutical, cosmetic, and medical compounds in United Arab Emirates, other GCC countries, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
JULPHAR Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gulf Pharmaceutical Industries P.S.C. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | د.إ1.30 |
52 Week High | د.إ1.78 |
52 Week Low | د.إ0.81 |
Beta | -0.40 |
1 Month Change | -11.56% |
3 Month Change | 3.17% |
1 Year Change | 40.24% |
3 Year Change | 0.78% |
5 Year Change | -3.70% |
Change since IPO | -11.69% |
Recent News & Updates
Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch
Apr 28Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are
Mar 25Recent updates
Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch
Apr 28Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are
Mar 25Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified
Oct 16Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Jan 15Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking
Nov 04Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals
Mar 26Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.
Feb 08Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like
Dec 14Shareholder Returns
JULPHAR | AE Pharmaceuticals | AE Market | |
---|---|---|---|
7D | -4.4% | -0.9% | 0.3% |
1Y | 40.2% | 18.3% | 13.4% |
Return vs Industry: JULPHAR exceeded the AE Pharmaceuticals industry which returned 18.3% over the past year.
Return vs Market: JULPHAR exceeded the AE Market which returned 13.4% over the past year.
Price Volatility
JULPHAR volatility | |
---|---|
JULPHAR Average Weekly Movement | 5.6% |
Pharmaceuticals Industry Average Movement | 4.9% |
Market Average Movement | 3.7% |
10% most volatile stocks in AE Market | 8.4% |
10% least volatile stocks in AE Market | 2.1% |
Stable Share Price: JULPHAR's share price has been volatile over the past 3 months compared to the AE market.
Volatility Over Time: JULPHAR's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of AE stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | n/a | Basel Nimer Ziyadeh | www.julphar.net |
Gulf Pharmaceutical Industries P.S.C., together with its subsidiaries, manufactures and sells medicines, drugs, and various other types of pharmaceutical, cosmetic, and medical compounds in United Arab Emirates, other GCC countries, and internationally. It operates through Manufacturing, Planet, Investments, and Others segment. The company offers generic medicines for pain and inflammation, antiviral, respiratory, anti-infectives, immunosuppressants and selective immunosuppressants, cardio care, CNS and psychiatry, vitamins and supplements, wound care management, dermatology, endocrine, gynecology and women care, anemia, antibiotics, decongestants and other nasal preparations, hyperkalemia and hyperphosphatemia, urinary antispasmodics, erectile dysfunction, benign prostatic hyperplasia, and gastrointestinal tract.
Gulf Pharmaceutical Industries P.S.C. Fundamentals Summary
JULPHAR fundamental statistics | |
---|---|
Market cap | د.إ1.50b |
Earnings (TTM) | د.إ46.00m |
Revenue (TTM) | د.إ1.34b |
Is JULPHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JULPHAR income statement (TTM) | |
---|---|
Revenue | د.إ1.34b |
Cost of Revenue | د.إ791.20m |
Gross Profit | د.إ552.80m |
Other Expenses | د.إ506.80m |
Earnings | د.إ46.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | 0.04 |
Gross Margin | 41.13% |
Net Profit Margin | 3.42% |
Debt/Equity Ratio | 39.9% |
How did JULPHAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/09/13 19:17 |
End of Day Share Price | 2025/09/12 00:00 |
Earnings | 2025/06/30 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gulf Pharmaceutical Industries P.S.C. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Rim Ben Salah Gharbi | AlphaMena |
null RESEARCH DEPARTMENT | Prime Research |